# Cerenome Inc. (CNSY)

Source: https://www.quantisnow.com/company/CNSY
Generated: 2026-11-19T21:29:43.116Z

- Ticker: CNSY
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- SEC CIK: 0001095981
- Website: https://www.plustherapeutics.com

## About

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

## Latest CNSY news and filings

- 2026-11-16 12:45 UTC [SEC Form 8-K] [Cerenome Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cerenome-inc-filed-sec-form-8-k-other-events-financial-statements-6792298)
- 2026-11-16 12:30 UTC [Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting](https://www.quantisnow.com/insight/cerenome-reports-interim-respect-lm-data-supporting-repeat-dosing-of-reyobiq-6792223)
- 2026-11-13 22:19 UTC [Earnings] [Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress](https://www.quantisnow.com/insight/cerenome-reports-third-quarter-2026-financial-results-and-business-highlights-6791452)
- 2026-11-13 22:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Cerenome Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-cerenome-inc-6791348)
- 2026-11-13 21:51 UTC [SEC Form 8-K] [Cerenome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cerenome-inc-filed-sec-form-8-k-results-of-operations-and-6791218)
- 2026-11-13 18:41 UTC [Earnings Date] [Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO](https://www.quantisnow.com/insight/brain-cancer-biotech-race-heats-up-as-neonc-nuvation-jazz-6790059)
- 2026-11-12 13:30 UTC [SEC Form 4] [Chief Business Officer Andrews Ronald Asbury was granted 92,858 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-andrews-ronald-asbury-was-granted-92858-stock-6786656)
- 2026-11-12 12:30 UTC [Earnings Date] [Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16](https://www.quantisnow.com/insight/cerenome-to-review-reyobiq-respect-lm-data-presented-at-sno-conference-6786227)
- 2026-11-10 12:30 UTC [Leadership Update] [Cerenome Appoints Director Ron Andrews as Chief Business Officer](https://www.quantisnow.com/insight/cerenome-appoints-director-ron-andrews-as-chief-business-officer-6782830)
- 2026-11-04 12:30 UTC [Cerenome Secures National In-Network Agreement with Aetna for CNSide®](https://www.quantisnow.com/insight/cerenome-secures-national-in-network-agreement-with-aetna-for-cnside-6771343)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CNSY
- Earnings history: https://www.quantisnow.com/earnings/CNSY
- Dividend history: https://www.quantisnow.com/dividends/CNSY
- Insider transactions: https://www.quantisnow.com/insiders/CNSY
- Options chain: https://www.quantisnow.com/options/CNSY
- SEC 8-K filings only: https://www.quantisnow.com/company/CNSY/8-k
- RSS and alerts for CNSY: https://www.quantisnow.com/docs/rss-feeds.md
